2022年12月19日

新領導人提升產品組合,以客戶為中心的商業功能,以及銷售和營銷執行鹽湖城,12月19日,2022(全球通訊社)——無數的遺傳學,Inc .(納斯達克:MYGN),一個領導者在基因檢測和精密醫學,今天宣布的5個高管幫助進一步加強公司的產品路線圖,改善商業執行。雷頓是負責領導跨組織的產品策略。他有超過15年的經驗在醫療和舉行各種產品在全球領導角色設備和軟件,最近在佛羅倫薩醫療產品的高級副總裁。法雷爾是負責領導品牌,為企業數字營銷和溝通策略。他擁有超過25年的經驗在醫療、領先的品牌戰略和成功的市場推廣項目生命科學和技術。他最近擔任CMO和麗莎Olson-Coombe Sema4控股集團創始團隊成員最近加入了無數的副總裁實驗室轉換。Olson-Coombe是負責領導無數的努力和升級的主要實驗室在鹽湖城和南舊金山。她擁有超過20年的經驗在管理診斷實驗室業務規模,最近擔任實驗室操作精確科學公司副總裁約翰·奧伯格將加入無數的高級業務發展有效的1月3日,2023年。奧伯格將負責種植業務合作和建設與生物技術公司合作,醫療保健網絡,衛生係統和學術合作夥伴。他有超過15年的經驗在醫療領域,基因組學和精密醫學,最近擔任業務發展主管Invitae公司總經理邁克爾·裏昂將加入無數腫瘤有效的1月3日,2023年。 Lyons will lead the oncology go-to-market strategy and oversee sales, marketing, medical affairs and customer service team members. He has more than 20 years of experience in healthcare, with expertise in the oncology space. He previously served as the SVP of North America at Novocure Ltd. “We are pleased to welcome Marc, Glenn, Lisa, John, and Michael to the Myriad team. They are all accomplished leaders who will each play an instrumental role in accelerating the growth of our commercial business forward and elevating our products to their full potential,” said Paul J. Diaz, president and CEO, Myriad Genetics. “Their combined depth of experience in healthcare and respective areas of expertise will continue to enrich our strong foundation for long-term sustainable growth, profitability and innovation.” About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com . Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to elevating the company’s product portfolio, customer-centric commercial capabilities and sales and marketing execution, accelerating the growth of the company’s commercial business, the company’s strong foundation for long-term sustainable growth, profitability and innovation, and Oberg and Lyons joining the company effective January 3, 2023. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Media Contact: